<DOC>
	<DOCNO>NCT01989611</DOCNO>
	<brief_summary>A prospective , open , multicenter , demonstrative PrEP , aim assess acceptability , feasibility safety chemoprophylaxis co-formulated emtricitabine / tenofovir disoproxil fumarate ( FTC / TDF ) administer orally , daily , MSM transgender woman . The demonstration project aim include 400 participant 12 month , 200 IPEC-Fiocruz , 100 CRT-SP 100 USP .</brief_summary>
	<brief_title>Implementation Pre-Exposure Prophylaxis ( PrEP ) HIV : A Demonstrative Project .</brief_title>
	<detailed_description>Subjects preliminarily eligible choose receive PrEP include obtain inform consent confirmation eligibility within 45 day screen visit . Once include , participant examine follow-up visit perform four week later evaluate evidence seroconversion HIV , medication compliance clinical toxicity . The second follow-up visit occur 12th week every 12 week successively ( quarterly ) . Quarterly visit include HIV testing , serum creatinine counsel medication compliance risk reduction . The study total 6 visit . In visit assessed risk , HIV test perform , monitor renal function dispense drug Truvada [ emtricitabine 1 tablet ( FTC ) / tenofovir ( TDF ) ( 200/300 mg ) day orally 12 month ] . Participants complete 12 month follow-up prematurely discontinue PrEP encourage return follow-up visit discontinuation medication monitoring status evaluation HIV resolution side effect .</detailed_description>
	<mesh_term>Emtricitabine , Tenofovir Disoproxil Fumarate Drug Combination</mesh_term>
	<mesh_term>Emtricitabine</mesh_term>
	<mesh_term>Tenofovir</mesh_term>
	<criteria>Male ( birth ) ; Willing able provide inform consent writing ; Age = &gt; 18 year ; infect HIV1 , accordance flowchart test Brazilian Ministry Health ; Evidence risk acquire HIV1 , include follow : 1 . Anal sex without condom two men transgender woman last 12 month , 2 . 2 episode anal sex least one partner HIV + last 12 month , 3 . Sex man trans woman diagnosis follow STDs last 12 month : syphilis , rectal gonorrhea chlamydial infection rectum . Able provide residential address contact phone , two personal contact would know whereabouts study period demonstrative ; Adequate renal function : Creatinine clearance &gt; = 60 ml / min , estimate formula modification diet renal disease ( MDRD , English 'Modification Diet Renal Disease ' ) within 45 day enrollment ; urine Tape negative result show trace protein within 45 day prior enrollment ; Signs symptom acute HIV infection , confirm laboratory examination subsequent sample ; Active severe infection previously diagnose , include active tuberculosis osteomyelitis infection require parenteral antibiotic ( except STD require intramuscular injection antibiotic ) ; clinically significant active medical problem , include heart disease poorly control ( eg , symptom ischemia , congestive heart failure ) previously diagnose malignancy , require additional treatment ; Patients positive test antigens hepatitis B surface ( HBsAg ) ; History pathological bone fracture unrelated trauma ; Patients use follow : ARV , include nucleoside inhibitor , nonnucleoside reverse transcriptase inhibitor , protease inhibitor antiretroviral agent study , treatment interferon ( alpha , beta , gamma ) interleukin ( e.g . , IL2 ) , potential significant nephrotoxic agent , agent may inhibit compete renal elimination via active tubular secretion ( eg probenecid ) / agent study ; Participation clinical trial use concomitant agent investigation , include placebocontrolled trial use agent ; Patients condition time inclusion study , accord opinion investigator , may prevent provision inform consent , make study participation unsafe , complicate data interpretation , interfere anyway achievement project objective .</criteria>
	<gender>Male</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>October 2015</verification_date>
</DOC>